Viewing data from:

LISRAYA

NDA

BREPOCITINIB TOSYLATE | N220106 | PRIOVANT THERAPEUTICS INC

1 strength2 unique patents1 unique exclusivity

Patent Timeline

2 unique patents, 1 exclusivity by expiration date

Active (2)TodayExclusivity

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

Today

9663526

Aug. 19, 2035

11197867

Aug. 19, 2035

NCE

Aug. 27, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Aug 28, 2026	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 30MG BASE

RLD

2 patents1 exclusivity▴

TABLET;ORAL | Approved: Aug 27, 2026

Patents (2)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
9663526Newly listed — daily FDA feed, not yet in monthly Orange Book edition	Aug 19, 2035	—	Yes	Yes	—	—
11197867Newly listed — daily FDA feed, not yet in monthly Orange Book edition	Aug 19, 2035	—	Yes	Yes	—	—

Exclusivities (1)

Code	Date	Status
NCENewly listed — daily FDA feed, not yet in monthly Orange Book edition	Aug 27, 2031	Active

Change History (1)

Recent changes detected for this application.

ADDED10/19/2026

Lisraya (brepocitinib tosylate) gained new chemical entity exclusivity expiring Aug 2031.

New: LISRAYA (BREPOCITINIB TOSYLATE) — exclusivity NCE exp 08/27/2031